These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 26717314)
1. Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment. Saleh L; Danser JA; van den Meiracker AH Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):94-9. PubMed ID: 26717314 [TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic-induced hypertension: the molecular basis of signaling network. Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493 [TBL] [Abstract][Full Text] [Related]
3. The Endothelin Type A Receptor as a Potential Therapeutic Target in Preeclampsia. Bakrania B; Duncan J; Warrington JP; Granger JP Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264495 [TBL] [Abstract][Full Text] [Related]
4. Endothelin-1 and antiangiogenesis. Lankhorst S; Danser AH; van den Meiracker AH Am J Physiol Regul Integr Comp Physiol; 2016 Feb; 310(3):R230-4. PubMed ID: 26511523 [TBL] [Abstract][Full Text] [Related]
5. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849 [TBL] [Abstract][Full Text] [Related]
6. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Kappers MH; Smedts FM; Horn T; van Esch JH; Sleijfer S; Leijten F; Wesseling S; Strevens H; Jan Danser AH; van den Meiracker AH Hypertension; 2011 Aug; 58(2):295-302. PubMed ID: 21670421 [TBL] [Abstract][Full Text] [Related]
7. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Maynard SE; Min JY; Merchan J; Lim KH; Li J; Mondal S; Libermann TA; Morgan JP; Sellke FW; Stillman IE; Epstein FH; Sukhatme VP; Karumanchi SA J Clin Invest; 2003 Mar; 111(5):649-58. PubMed ID: 12618519 [TBL] [Abstract][Full Text] [Related]
8. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Yang F; Jin C; Jiang YJ; Li J; Di Y; Fu DL Expert Rev Anticancer Ther; 2011 Apr; 11(4):541-9. PubMed ID: 21504321 [TBL] [Abstract][Full Text] [Related]
9. Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Wang W; Parchim NF; Iriyama T; Luo R; Zhao C; Liu C; Irani RA; Zhang W; Ning C; Zhang Y; Blackwell SC; Chen L; Tao L; Hicks MJ; Kellems RE; Xia Y Hypertension; 2014 Mar; 63(3):595-606. PubMed ID: 24324043 [TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Suzuki H; Ohkuchi A; Matsubara S; Takei Y; Murakami M; Shibuya M; Suzuki M; Sato Y Hypertension; 2009 Nov; 54(5):1129-35. PubMed ID: 19786649 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987 [TBL] [Abstract][Full Text] [Related]
12. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779 [TBL] [Abstract][Full Text] [Related]
14. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Maynard SE; Venkatesha S; Thadhani R; Karumanchi SA Pediatr Res; 2005 May; 57(5 Pt 2):1R-7R. PubMed ID: 15817508 [TBL] [Abstract][Full Text] [Related]
15. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. Saleh L; Verdonk K; Visser W; van den Meiracker AH; Danser AH Ther Adv Cardiovasc Dis; 2016 Oct; 10(5):282-93. PubMed ID: 26755746 [TBL] [Abstract][Full Text] [Related]
17. Endothelin: key mediator of hypertension in preeclampsia. George EM; Granger JP Am J Hypertens; 2011 Sep; 24(9):964-9. PubMed ID: 21677700 [TBL] [Abstract][Full Text] [Related]
18. The Endothelin System: A Critical Player in the Pathophysiology of Preeclampsia. Granger JP; Spradley FT; Bakrania BA Curr Hypertens Rep; 2018 Apr; 20(4):32. PubMed ID: 29637419 [TBL] [Abstract][Full Text] [Related]
19. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Verdonk K; Saleh L; Lankhorst S; Smilde JE; van Ingen MM; Garrelds IM; Friesema EC; Russcher H; van den Meiracker AH; Visser W; Danser AH Hypertension; 2015 Jun; 65(6):1316-23. PubMed ID: 25870197 [TBL] [Abstract][Full Text] [Related]
20. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Kim YN; Lee DS; Jeong DH; Sung MS; Kim KT Prenat Diagn; 2009 May; 29(5):464-70. PubMed ID: 19242927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]